
Newly Approved ADCs Expand Options in HR+ Metastatic Breast Cancer
Following the recent FDA approvals of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) and datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) investigators now have 3 antibody-drug conjugate (ADC) choices in the hormone receptor (HR)–positive breast cancer …